Cell specific control of coagulation and fibrinolysis within the lung

• References

• 1 Albertine KH, Williams MC, Hyde DM. Anatomy of the Lungs. Murray JF, Nadel JA. Textbook of respiratory medicine. Philadelphia: W.B. Saunders, Co; 2000: 12-36.
• 2 Wygrecka M, Markart P, Kuchenbuch T. et al. Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalative versus intravenous endotoxin application. Thromb Haemost 2004; 92: 529-40.
• 3 Gross TJ, Simon RH, Sitrin RG. Tissue factor procoagulant expression by rat alveolar epithelial cells. Am J Respir Cell Mol Biol 1992; 06: 397-403.
• 4 Chapman Jr HA, Allen CL, Stone OL. et al. Human alveolar macrophages synthesize factor VII in vitro. Possible role in interstitial lung disease. J Clin Invest 1985; 75: 2030-7.
• 5 McGee MP, Wallin R, Wheeler FB. et al. Initiation of the extrinsic pathway of coagulation by human and rabbit alveolar macrophages: a kinetic study. Blood 1989; 74: 1583-90.
• 6 Idell S, James KK, Levin EG. et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84: 695-705.
• 7 Idell S, Koenig KB, Fair DS. et al. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991; 261: L240-8.
• 8 Seeger W, Hubel J, Klapettek K. et al. Procoagulant activity in bronchoalveolar lavage of severely traumatized patients - relation to the development of acute respiratory distress. Thromb Res 1991; 61: 53-64.
• 9 Seeger W, Elssner A, Gunther A. et al. Lung surfactant phospholipids associate with polymerizing fibrin: loss of surface activity. Am J Respir Cell Mol Biol 1993; 09: 213-20.
• 10 Idell S, Mazar AP, Bitterman P. et al. Fibrin turnover in lung inflammation and neoplasia. Am J Respir Crit Care Med 2001; 163: 578-84.
• 11 Chapman HA, Allen CL, Stone OL. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 1986; 133: 437-43.
• 12 Idell S, James KK, Gillies C. et al. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am J Pathol 1989; 135: 387-99.
• 13 Bertozzi P, Astedt B, Zenzius L. et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990; 322: 890-7.
• 14 Gunther A, Lubke N, Ermert M. et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003; 168: 1358-65.
• 15 Idell S, Peterseon BT, Gonzalez KK. et al. Local abnormalities of coagulation and fibrinolysis and alveolar fibrin deposition in sheep with oleic acid-induced lung injury. Am Rev Respir Dis 1988; 138: 1282-94.
• 16 Nakstad B, Lyberg T, Skjonsberg OH. et al. Local activation of the coagulation and fibrinolysis systems in lung disease. Thromb Res 1990; 57: 827-38.
• 17 Kotani I, Sato A, Hayakawa H. et al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995; 77: 493-504.
• 18 Olman MA, Mackman N, Gladson CL. et al. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995; 96: 1621-30.
• 19 Fuchs-Buder T, de Moerloose P, Ricou B. et al. Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 163-7.
• 20 Gunther A, Mosavi P, Heinemann S. et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-62.
• 21 Miller DL, Welty-Wolf K, Carraway MS. et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002; 26: 650-8.
• 22 Hart DA, Whidden P, Green F. et al. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin Invest Med 1994; 17: 69-76.
• 23 Ikeda T, Hirose N, Koto H. et al. Fibrin deposition and fibrinolysis in the pathogenesis of pulmonary fibrosis. Nippon Kyobu Shikkan Gakkai Zasshi 1989; 27: 448-51.
• 24 Eitzman DT, McCoy RD, Zheng X. et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-7.
• 25 Sisson TH, Hattori N, Xu Y. et al. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther 1999; 10: 2315-23.
• 26 Sisson TH, Hanson KE, Subbotina N. et al. Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice. Am J Physiol 2002; 283: L1023-L1032.
• 27 Hattori N, Degen JL, Sisson TH. et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106: 1341-50.
• 28 Swaisgood CM, French EL, Noga C. et al. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 2000; 157: 177-87.
• 29 Kaplan RL, Sahn SA, Petty TL. Incidence and outcome of the respiratory distress syndrome in gram-negative sepsis. Arch Intern Med 1979; 139: 867-9.
• 30 Strieter RM, Lynch 3rd JP, Basha MA. et al. Host responses in mediating sepsis and adult respiratory distress syndrome. Semin Respir Infect 1990; 05: 233-47.
• 31 Liu AH. Something old, something new: indoor endotoxin, allergens and asthma. Paediatr Respir Rev 2004; 05 Suppl A: S65-71.
• 32 Erlich J, Fearns C, Mathison J. et al. Lipopolysaccharide induction of tissue factor expression in rabbits. Infect Immun 1999; 67: 2540-6.
• 33 Savov JD, Brass DM, Berman KG. et al. Fibrinolysis in LPS-induced chronic airway disease. Am J Physiol Lung 2003; 285: L940-8.
• 34 Barazzone C, Belin D, Piguet PF. et al. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest 1996; 98: 2666-73.
• 35 Lardot C, Delos M, Lison D. Upregulation of urokinase in alveolar macrophages and lung tissue in response to silica particles. Am J Physiol 1998; 274: L1040-8.
• 36 Lang IM, Moser KM, Schleef RR. Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism. Arterioscler Thromb Vasc Biol 1998; 18: 808-15.
• 37 Pinsky DJ, Liao H, Lawson CA. et al. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 1998; 102: 919-28.
• 38 Levi M, Moons L, Bouche A. et al. Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. Circulation 2001; 103: 2014-20.
• 39 Solberg H, Ploug M, Hoyer-Hansen G. et al. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem 2001; 49: 237-46.
• 40 Muth H, Maus U, Wygrecka M. et al. Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha. Crit Care Med 2004; 32: 217-26.
• 41 Nakstad B, Haugen T, Skjonsberg OH. et al. Expression of leukocyte integrins and tissue factor in mononuclear phagocytes. Eur Respir J 1998; 12: 601-6.